Business
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE
About this update from Femasys Inc.
[{"type":"text","content":"FemaSeed® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces the United States Patent and Trademark Office (“USPTO”) issued a Notice of Allowance for U.S. Patent Application 18/443,798 further strengthening Femasys’ intellectual property position and coverage for the Company’s infertility therapeutic product FemaSeed® Intratubal Insemination. Femasys expects the resulting patent, when issued, will have an anticipated expiration in 2044 at the earliest. Femasys intends to continue to prosecute additional patent applications to further enhance its existing patent portfolio protecting FemaSeed® along with FemBloc® permanent birth control, the Company’s late-stage product candidate, in addition to the Company’s other existing available diagnostic products, FemVue®, FemCath®, and FemCerv®. “The allowance of claims for the FemaSeed infertility treatment is another important milestone in extending protection for this revolutionary infertility solution for women and couples seeking assistance in becoming pregnant, which is currently being marketed in the U.S. and Spain,” stated Kathy Lee-Sepsick, Femasys’ CEO. “Expansion of our patent portfolio, which consists of over 180 patents globally, demonstrates our strong commitment to protecting the innovation and commercial opportunity of FemaSeed, as well as our entire suite of products for women seeking better, lower cost, and more accessible options.” About FemaSeedFemaSeed® is an innovative advancement in artificial insemination, designed to enhance fertilization by precisely delivering sperm into the fallopian tube, the natural site of conception. It is intended to be a first-line therapeutic choice for infertile women, men, and couples seeking pregnancy through insemination, offering a safe, accessible, and cost-effective approach. FemaSeed® is a revolutionary device that allows for the expansion of practice services by enabling healthcare professionals with a more affordable and safer alternative to assisted reproductive methods, such as in vitro...